Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tivozanib in Recurrent Glioblastoma
NCT01846871Phase 2Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Jun 2013
- Primary completion
- Sep 2014
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of tivozanib in glioblastoma (GBM), sponsored by Massachusetts General Hospital. Started Jun 2013; status: completed.
02
Drugs
tivozanib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT01846871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01846871.